Here we introduce CTIM-76, a CLDN6 T-cell engager antibody as a potential treatment of ovarian, endometrial, and other solid tumors....CTIM-76 shows a combination of potent killing of CLDN6-expressing cells, no killing of cells expressing other closely related claudin family members, and excellent productivity and developability….The exquisite specificity of CTIM-76 suggests the potential to address the need for potent therapeutic modalities for ovarian and other cancers without compromising patient safety.